Faculty Opinions recommendation of Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.

Background: Numerous treatments are available for cutaneous T-cell lymphoma (CTCL), including systemic retinoids. Very few data are available on topical retinoids. Objectives: The aim of this study was to evaluate the safety and efficiency of tazarotene as monotherapy for early-stage CTCL. Methods: An open-label, prospective study of tazarotene as monotherapy for stages IA to IIA CTCL was conducted. Index lesions on 10 patients were followed for 6 months on treatment, plus at least 6 months off treatment. Results: Six patients (60%) showed complete response (CR). Erythema, scaling, thickness, and lesion area decreased progressively throughout treatment. The mean time to CR was 3.8 months; CR was durable for at least 6 months in 83%. Of the 4 patients (40%) without CR, 2 (20%) had stable disease and 2 (20%) stopped the medication because of local side effects; none showed progression. Conclusions: This is the first Canadian trial providing evidence that topical tazarotene has excellent potential as a monotherapy agent for stages I to IIA CTCL.

Download Full-text

28487 Extracorporeal photopheresis for early stage cutaneous T-cell lymphoma: Race-based differences in treatment utilization and response

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.209 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB46

Author(s):

Priyanka Kumar ◽

Amarachi Eseonu ◽

Courtney Johnson ◽

Noori Kim ◽

Sima Rozati

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

Early Stage ◽

T Cell Lymphoma ◽

Treatment Utilization ◽

Cutaneous T Cell Lymphoma ◽

Extracorporeal Photopheresis

Download Full-text

Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage

Journal of Biomedicine and Biotechnology ◽

10.1155/2010/805907 ◽

2010 ◽

Vol 2010 ◽

pp. 1-5 ◽

Cited By ~ 6

Author(s):

Anna Vasku ◽

Julie Bienertova Vasku ◽

Miroslav Nečas ◽

Vladimir Vasku

Keyword(s):

T Cell ◽

Skin Diseases ◽

Cell Lymphoma ◽

Early Stage ◽

Clinical Diagnostics ◽

T Cell Lymphoma ◽

Matrix Metalloproteinase 2 ◽

Potential Candidate ◽

Cutaneous T Cell Lymphoma ◽

History Of

The aim of the study was to investigate the DNA polymorphic genotype in MMP-2 promoter gene as a potential candidate region for the development of the cutaneous T-cell lymphoma (CTCL) and/or its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls of similar age and sex distribution, without personal or family history of chronic skin diseases and without personal history of malignancy. The three selected polymorphisms in the promoter of MMP-2 gene (−1575G/A,−1306C/T, and−790T/G) were determined using the PCR-based methodology with RFLP. In our cohort, the associatedGGCCTTMMP-2 promoter genotype was highly significantly more frequent in CTCL-Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP-2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in the early stages.

Download Full-text